JP2023002483A - 昆虫細胞におけるアデノ随伴ウイルスベクターの産生 - Google Patents
昆虫細胞におけるアデノ随伴ウイルスベクターの産生 Download PDFInfo
- Publication number
- JP2023002483A JP2023002483A JP2022098808A JP2022098808A JP2023002483A JP 2023002483 A JP2023002483 A JP 2023002483A JP 2022098808 A JP2022098808 A JP 2022098808A JP 2022098808 A JP2022098808 A JP 2022098808A JP 2023002483 A JP2023002483 A JP 2023002483A
- Authority
- JP
- Japan
- Prior art keywords
- vector
- aav
- clipping
- insect cells
- raav
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000238631 Hexapoda Species 0.000 title claims abstract description 151
- 239000013598 vector Substances 0.000 title claims abstract description 135
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 38
- 241000702421 Dependoparvovirus Species 0.000 title claims abstract description 32
- 239000013608 rAAV vector Substances 0.000 claims abstract description 178
- 238000000034 method Methods 0.000 claims abstract description 154
- 101710081079 Minor spike protein H Proteins 0.000 claims abstract description 135
- 241000701447 unidentified baculovirus Species 0.000 claims abstract description 130
- 238000000338 in vitro Methods 0.000 claims abstract description 101
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 98
- 150000001413 amino acids Chemical class 0.000 claims abstract description 66
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims abstract description 23
- 238000012258 culturing Methods 0.000 claims abstract description 21
- 230000001965 increasing effect Effects 0.000 claims abstract description 18
- 101710132601 Capsid protein Proteins 0.000 claims description 211
- 101710197658 Capsid protein VP1 Proteins 0.000 claims description 211
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 claims description 211
- 101710108545 Viral protein 1 Proteins 0.000 claims description 211
- 108090000623 proteins and genes Proteins 0.000 claims description 117
- 102000004169 proteins and genes Human genes 0.000 claims description 72
- 108700019146 Transgenes Proteins 0.000 claims description 70
- 239000000203 mixture Substances 0.000 claims description 44
- 230000003612 virological effect Effects 0.000 claims description 44
- 229960000301 factor viii Drugs 0.000 claims description 34
- 108010054218 Factor VIII Proteins 0.000 claims description 32
- 239000003114 blood coagulation factor Substances 0.000 claims description 32
- 102000001690 Factor VIII Human genes 0.000 claims description 31
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 claims description 31
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 20
- 239000001301 oxygen Substances 0.000 claims description 20
- 229910052760 oxygen Inorganic materials 0.000 claims description 20
- 238000003556 assay Methods 0.000 claims description 17
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 claims description 15
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 claims description 15
- 238000003753 real-time PCR Methods 0.000 claims description 13
- 102100022641 Coagulation factor IX Human genes 0.000 claims description 12
- 101000982032 Homo sapiens Myosin-binding protein C, cardiac-type Proteins 0.000 claims description 11
- 102100026771 Myosin-binding protein C, cardiac-type Human genes 0.000 claims description 11
- 238000001818 capillary gel electrophoresis Methods 0.000 claims description 11
- 238000004949 mass spectrometry Methods 0.000 claims description 11
- 238000001262 western blot Methods 0.000 claims description 11
- 108010076282 Factor IX Proteins 0.000 claims description 9
- 229960004222 factor ix Drugs 0.000 claims description 9
- 239000001963 growth medium Substances 0.000 claims description 9
- 239000013647 rAAV8 vector Substances 0.000 claims description 9
- 102100027591 Copper-transporting ATPase 2 Human genes 0.000 claims description 8
- 101000936280 Homo sapiens Copper-transporting ATPase 2 Proteins 0.000 claims description 8
- 229940009550 c1 esterase inhibitor Drugs 0.000 claims description 8
- 239000006143 cell culture medium Substances 0.000 claims description 8
- 238000007398 colorimetric assay Methods 0.000 claims description 8
- TUGDLVFMIQZYPA-UHFFFAOYSA-N tetracopper;tetrazinc Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2] TUGDLVFMIQZYPA-UHFFFAOYSA-N 0.000 claims description 8
- 238000002965 ELISA Methods 0.000 claims description 7
- 101710170620 Copper-transporting P-type ATPase Proteins 0.000 claims description 6
- 239000013645 rAAV1 vector Substances 0.000 claims description 6
- 102100023804 Coagulation factor VII Human genes 0.000 claims description 4
- 108010023321 Factor VII Proteins 0.000 claims description 4
- 229940012413 factor vii Drugs 0.000 claims description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 2
- 229940019700 blood coagulation factors Drugs 0.000 claims description 2
- 230000009089 cytolysis Effects 0.000 claims 1
- 239000002245 particle Substances 0.000 abstract description 22
- 230000003389 potentiating effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 278
- 150000007523 nucleic acids Chemical class 0.000 description 105
- 102000039446 nucleic acids Human genes 0.000 description 79
- 108020004707 nucleic acids Proteins 0.000 description 79
- 210000000234 capsid Anatomy 0.000 description 68
- 235000018102 proteins Nutrition 0.000 description 67
- 235000001014 amino acid Nutrition 0.000 description 62
- 229940024606 amino acid Drugs 0.000 description 59
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 50
- 108090000765 processed proteins & peptides Proteins 0.000 description 44
- 102000004196 processed proteins & peptides Human genes 0.000 description 37
- 208000015181 infectious disease Diseases 0.000 description 30
- 229920001184 polypeptide Polymers 0.000 description 30
- 108090000565 Capsid Proteins Proteins 0.000 description 27
- 102100023321 Ceruloplasmin Human genes 0.000 description 27
- 241000700605 Viruses Species 0.000 description 27
- 230000014509 gene expression Effects 0.000 description 27
- 201000010099 disease Diseases 0.000 description 26
- 208000035475 disorder Diseases 0.000 description 24
- 239000002773 nucleotide Substances 0.000 description 24
- 125000003729 nucleotide group Chemical group 0.000 description 23
- 101000805768 Banna virus (strain Indonesia/JKT-6423/1980) mRNA (guanine-N(7))-methyltransferase Proteins 0.000 description 21
- 101000686790 Chaetoceros protobacilladnavirus 2 Replication-associated protein Proteins 0.000 description 21
- 101000864475 Chlamydia phage 1 Internal scaffolding protein VP3 Proteins 0.000 description 21
- 102000053602 DNA Human genes 0.000 description 21
- 108020004414 DNA Proteins 0.000 description 21
- 101000803553 Eumenes pomiformis Venom peptide 3 Proteins 0.000 description 21
- 101000583961 Halorubrum pleomorphic virus 1 Matrix protein Proteins 0.000 description 21
- 108091028043 Nucleic acid sequence Proteins 0.000 description 21
- 230000000694 effects Effects 0.000 description 18
- 102000040430 polynucleotide Human genes 0.000 description 18
- 108091033319 polynucleotide Proteins 0.000 description 18
- 239000002157 polynucleotide Substances 0.000 description 18
- 238000006467 substitution reaction Methods 0.000 description 18
- 238000003306 harvesting Methods 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 16
- 230000006870 function Effects 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 15
- 239000013604 expression vector Substances 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- 239000013603 viral vector Substances 0.000 description 12
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 11
- 241000288906 Primates Species 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 230000001105 regulatory effect Effects 0.000 description 11
- 230000010076 replication Effects 0.000 description 10
- 238000010361 transduction Methods 0.000 description 10
- 230000026683 transduction Effects 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- 239000013607 AAV vector Substances 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 230000010354 integration Effects 0.000 description 9
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 8
- 102000010977 Phospholipase A2 domains Human genes 0.000 description 8
- 108050001165 Phospholipase A2 domains Proteins 0.000 description 8
- 238000004422 calculation algorithm Methods 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 238000001415 gene therapy Methods 0.000 description 8
- 238000004806 packaging method and process Methods 0.000 description 8
- 102100026735 Coagulation factor VIII Human genes 0.000 description 7
- 108091026890 Coding region Proteins 0.000 description 7
- 241000125945 Protoparvovirus Species 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 210000004897 n-terminal region Anatomy 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 229920002477 rna polymer Polymers 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000011084 recovery Methods 0.000 description 6
- 239000004055 small Interfering RNA Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- -1 AAV6 capsid) Substances 0.000 description 5
- 101100524319 Adeno-associated virus 2 (isolate Srivastava/1982) Rep52 gene Proteins 0.000 description 5
- 101100524324 Adeno-associated virus 2 (isolate Srivastava/1982) Rep78 gene Proteins 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 5
- 101800001415 Bri23 peptide Proteins 0.000 description 5
- 101800000655 C-terminal peptide Proteins 0.000 description 5
- 102400000107 C-terminal peptide Human genes 0.000 description 5
- 208000009292 Hemophilia A Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000006337 proteolytic cleavage Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 101100524317 Adeno-associated virus 2 (isolate Srivastava/1982) Rep40 gene Proteins 0.000 description 4
- 101100524321 Adeno-associated virus 2 (isolate Srivastava/1982) Rep68 gene Proteins 0.000 description 4
- 230000004543 DNA replication Effects 0.000 description 4
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 4
- 102100025907 Dyslexia-associated protein KIAA0319-like protein Human genes 0.000 description 4
- 101710205593 Dyslexia-associated protein KIAA0319-like protein Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 206010019860 Hereditary angioedema Diseases 0.000 description 4
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 4
- 108700011259 MicroRNAs Proteins 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 108020004459 Small interfering RNA Proteins 0.000 description 4
- 241000256251 Spodoptera frugiperda Species 0.000 description 4
- 102100023532 Synaptic functional regulator FMR1 Human genes 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 229940088679 drug related substance Drugs 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 238000010362 genome editing Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000009126 molecular therapy Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 230000001131 transforming effect Effects 0.000 description 4
- 230000010415 tropism Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- 108020005544 Antisense RNA Proteins 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 241000282465 Canis Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 201000003542 Factor VIII deficiency Diseases 0.000 description 3
- 102000004547 Glucosylceramidase Human genes 0.000 description 3
- 108010017544 Glucosylceramidase Proteins 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 108091092195 Intron Proteins 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 241000209094 Oryza Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100029081 Proteasome subunit beta type-10 Human genes 0.000 description 3
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 description 3
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 3
- 101710181917 Serine proteinase inhibitor 1 Proteins 0.000 description 3
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000003184 complementary RNA Substances 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 208000009429 hemophilia B Diseases 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000013609 scAAV vector Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 229910052727 yttrium Inorganic materials 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 2
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 2
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 2
- 102000055025 Adenosine deaminases Human genes 0.000 description 2
- 241000256173 Aedes albopictus Species 0.000 description 2
- 101710095342 Apolipoprotein B Proteins 0.000 description 2
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 2
- 102000053640 Argininosuccinate synthases Human genes 0.000 description 2
- 108700024106 Argininosuccinate synthases Proteins 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 101150100050 CLN2 gene Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102000005600 Cathepsins Human genes 0.000 description 2
- 108010084457 Cathepsins Proteins 0.000 description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 description 2
- 108091004554 Copper Transport Proteins Proteins 0.000 description 2
- 102000020856 Copper Transport Proteins Human genes 0.000 description 2
- 241000709675 Coxsackievirus B3 Species 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010054265 Factor VIIa Proteins 0.000 description 2
- 108010014173 Factor X Proteins 0.000 description 2
- 108010071289 Factor XIII Proteins 0.000 description 2
- 108010032606 Fragile X Mental Retardation Protein Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 description 2
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 2
- 208000031220 Hemophilia Diseases 0.000 description 2
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 2
- 101000828537 Homo sapiens Synaptic functional regulator FMR1 Proteins 0.000 description 2
- 101000662686 Homo sapiens Torsin-1A Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 208000015439 Lysosomal storage disease Diseases 0.000 description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 description 2
- 102100022437 Myotonin-protein kinase Human genes 0.000 description 2
- 102000003697 P-type ATPases Human genes 0.000 description 2
- 108090000069 P-type ATPases Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 102100026918 Phospholipase A2 Human genes 0.000 description 2
- 108010058864 Phospholipases A2 Proteins 0.000 description 2
- 108010071690 Prealbumin Proteins 0.000 description 2
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 description 2
- 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 2
- 108050005569 Proteasome subunit beta type 8 Proteins 0.000 description 2
- 101710084225 Proteasome subunit beta type-10 Proteins 0.000 description 2
- 102100035760 Proteasome subunit beta type-8 Human genes 0.000 description 2
- 101710094466 Proteasome subunit beta type-9 Proteins 0.000 description 2
- 101800004937 Protein C Proteins 0.000 description 2
- 102000017975 Protein C Human genes 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 description 2
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 101800001700 Saposin-D Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 229940122055 Serine protease inhibitor Drugs 0.000 description 2
- 101710102218 Serine protease inhibitor Proteins 0.000 description 2
- 102100026219 Serine/threonine-protein kinase N3 Human genes 0.000 description 2
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 description 2
- 241000270295 Serpentes Species 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 241000255588 Tephritidae Species 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 2
- 102100037454 Torsin-1A Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102100030986 Transgelin-3 Human genes 0.000 description 2
- 108050006165 Transgelin-3 Proteins 0.000 description 2
- 102000009190 Transthyretin Human genes 0.000 description 2
- 108010039203 Tripeptidyl-Peptidase 1 Proteins 0.000 description 2
- 102100034197 Tripeptidyl-peptidase 1 Human genes 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 208000018839 Wilson disease Diseases 0.000 description 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 102000005840 alpha-Galactosidase Human genes 0.000 description 2
- 108010030291 alpha-Galactosidase Proteins 0.000 description 2
- 108010028144 alpha-Glucosidases Proteins 0.000 description 2
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 208000031514 autosomal recessive nonsyndromic hearing loss 1A Diseases 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000008614 cellular interaction Effects 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 229940109357 desoxyribonuclease Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000011190 diabetic macular edema Diseases 0.000 description 2
- 210000000188 diaphragm Anatomy 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 210000003027 ear inner Anatomy 0.000 description 2
- 210000003372 endocrine gland Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 229940012414 factor viia Drugs 0.000 description 2
- 229940012426 factor x Drugs 0.000 description 2
- 229940012444 factor xiii Drugs 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 230000009395 genetic defect Effects 0.000 description 2
- 201000004502 glycogen storage disease II Diseases 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 208000010710 hepatitis C virus infection Diseases 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000012212 insulator Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000000185 intracerebroventricular administration Methods 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 238000001499 laser induced fluorescence spectroscopy Methods 0.000 description 2
- 208000025014 late infantile neuronal ceroid lipofuscinosis Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 208000021039 metastatic melanoma Diseases 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 210000004248 oligodendroglia Anatomy 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 210000002997 osteoclast Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 108010056274 polo-like kinase 1 Proteins 0.000 description 2
- 208000030761 polycystic kidney disease Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229960000856 protein c Drugs 0.000 description 2
- 230000004853 protein function Effects 0.000 description 2
- 108010061151 protein kinase N Proteins 0.000 description 2
- 210000002097 psoas muscle Anatomy 0.000 description 2
- 239000013646 rAAV2 vector Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 108010054126 retinoid isomerohydrolase Proteins 0.000 description 2
- 108010047866 ribonucleotide reductase M2 Proteins 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000003001 serine protease inhibitor Substances 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 210000002437 synoviocyte Anatomy 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical class CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- 108010046716 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) Proteins 0.000 description 1
- 108091027075 5S-rRNA precursor Proteins 0.000 description 1
- 101150091481 ATP7 gene Proteins 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- 101710147490 Ataxin-8 Proteins 0.000 description 1
- 102100026565 Ataxin-8 Human genes 0.000 description 1
- 102000014461 Ataxins Human genes 0.000 description 1
- 108010078286 Ataxins Proteins 0.000 description 1
- 102000004321 Atrophin-1 Human genes 0.000 description 1
- 102100020741 Atrophin-1 Human genes 0.000 description 1
- 108090000806 Atrophin-1 Proteins 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 101100545099 Bacillus subtilis (strain 168) yxiH gene Proteins 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000014817 CACNA1A Human genes 0.000 description 1
- 102000001902 CC Chemokines Human genes 0.000 description 1
- 108010040471 CC Chemokines Proteins 0.000 description 1
- 208000035545 CNGA3-related retinopathy Diseases 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 101100179596 Caenorhabditis elegans ins-3 gene Proteins 0.000 description 1
- 101100029886 Caenorhabditis elegans lov-1 gene Proteins 0.000 description 1
- 208000022526 Canavan disease Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000004046 Caspase-2 Human genes 0.000 description 1
- 108090000552 Caspase-2 Proteins 0.000 description 1
- 108010059081 Cathepsin A Proteins 0.000 description 1
- 102000005572 Cathepsin A Human genes 0.000 description 1
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 1
- 208000033810 Choroidal dystrophy Diseases 0.000 description 1
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000006992 Color Vision Defects Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 108010022637 Copper-Transporting ATPases Proteins 0.000 description 1
- 102100027587 Copper-transporting ATPase 1 Human genes 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102100029142 Cyclic nucleotide-gated cation channel alpha-3 Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000003849 Cytochrome P450 Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 102100026139 DNA damage-inducible transcript 4 protein Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010033174 Deoxycytidine kinase Proteins 0.000 description 1
- 102100029588 Deoxycytidine kinase Human genes 0.000 description 1
- 102000002148 Diacylglycerol O-acyltransferase Human genes 0.000 description 1
- 108010001348 Diacylglycerol O-acyltransferase Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- 102000003869 Frataxin Human genes 0.000 description 1
- 108090000217 Frataxin Proteins 0.000 description 1
- 208000024412 Friedreich ataxia Diseases 0.000 description 1
- 102100035233 Furin Human genes 0.000 description 1
- 108090001126 Furin Proteins 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- 102100023364 Ganglioside GM2 activator Human genes 0.000 description 1
- 101710201362 Ganglioside GM2 activator Proteins 0.000 description 1
- 102100037156 Gap junction beta-2 protein Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- 102000030595 Glucokinase Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101710191387 Guanylate cyclase 2D Proteins 0.000 description 1
- 241000255990 Helicoverpa Species 0.000 description 1
- 241001147381 Helicoverpa armigera Species 0.000 description 1
- 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 1
- 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 102000002268 Hexosaminidases Human genes 0.000 description 1
- 108010000540 Hexosaminidases Proteins 0.000 description 1
- 101000873082 Homo sapiens Ataxin-1 Proteins 0.000 description 1
- 101000785083 Homo sapiens Atrophin-1 Proteins 0.000 description 1
- 101000771071 Homo sapiens Cyclic nucleotide-gated cation channel alpha-3 Proteins 0.000 description 1
- 101000912753 Homo sapiens DNA damage-inducible transcript 4 protein Proteins 0.000 description 1
- 101000954092 Homo sapiens Gap junction beta-2 protein Proteins 0.000 description 1
- 101001124388 Homo sapiens NPC intracellular cholesterol transporter 1 Proteins 0.000 description 1
- 101001124792 Homo sapiens Proteasome subunit beta type-10 Proteins 0.000 description 1
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 description 1
- 101001070470 Homo sapiens Protein GPR108 Proteins 0.000 description 1
- 101001000998 Homo sapiens Protein phosphatase 1 regulatory subunit 12C Proteins 0.000 description 1
- 101000701517 Homo sapiens Putative protein ATXN8OS Proteins 0.000 description 1
- 101000814438 Homo sapiens Retinoschisin Proteins 0.000 description 1
- 101000935117 Homo sapiens Voltage-dependent P/Q-type calcium channel subunit alpha-1A Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 208000027747 Kennedy disease Diseases 0.000 description 1
- 102000005706 Keratin-6 Human genes 0.000 description 1
- 108010070557 Keratin-6 Proteins 0.000 description 1
- 102000010638 Kinesin Human genes 0.000 description 1
- 108010063296 Kinesin Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 1
- 102100022119 Lipoprotein lipase Human genes 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091007780 MiR-122 Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- 108010006140 N-sulfoglucosamine sulfohydrolase Proteins 0.000 description 1
- 102100027661 N-sulphoglucosamine sulphohydrolase Human genes 0.000 description 1
- 102100029565 NPC intracellular cholesterol transporter 1 Human genes 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 208000009869 Neu-Laxova syndrome Diseases 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 description 1
- 102000004132 Ornithine aminotransferases Human genes 0.000 description 1
- 108090000691 Ornithine aminotransferases Proteins 0.000 description 1
- 102000007981 Ornithine carbamoyltransferase Human genes 0.000 description 1
- 101710198224 Ornithine carbamoyltransferase, mitochondrial Proteins 0.000 description 1
- 208000008071 Parvoviridae Infections Diseases 0.000 description 1
- 206010057343 Parvovirus infection Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100034142 Protein GPR108 Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000006478 Protein Phosphatase 2 Human genes 0.000 description 1
- 108010058956 Protein Phosphatase 2 Proteins 0.000 description 1
- 102100035620 Protein phosphatase 1 regulatory subunit 12C Human genes 0.000 description 1
- 101710150114 Protein rep Proteins 0.000 description 1
- 102100030469 Putative protein ATXN8OS Human genes 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 101710088575 Rab escort protein 1 Proteins 0.000 description 1
- 101710108890 Rab proteins geranylgeranyltransferase component A 1 Proteins 0.000 description 1
- 102100022881 Rab proteins geranylgeranyltransferase component A 1 Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 101710152114 Replication protein Proteins 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 102100039507 Retinoschisin Human genes 0.000 description 1
- 102100040756 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 102000005890 Spectrin Human genes 0.000 description 1
- 108010019965 Spectrin Proteins 0.000 description 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 description 1
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 description 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
- 241000256247 Spodoptera exigua Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 102000005262 Sulfatase Human genes 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 101710086566 T-box transcription factor T Proteins 0.000 description 1
- 102100033130 T-box transcription factor T Human genes 0.000 description 1
- 102000006467 TATA-Box Binding Protein Human genes 0.000 description 1
- 108010044281 TATA-Box Binding Protein Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102100022356 Tyrosine-protein kinase Mer Human genes 0.000 description 1
- 208000014769 Usher Syndromes Diseases 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 102100025330 Voltage-dependent P/Q-type calcium channel subunit alpha-1A Human genes 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 208000002771 achromatopsia 2 Diseases 0.000 description 1
- 108091006088 activator proteins Proteins 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
- 238000013320 baculovirus expression vector system Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 108010018804 c-Mer Tyrosine Kinase Proteins 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003591 cerebellar nuclei Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 208000003571 choroideremia Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 201000007254 color blindness Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000013501 data transformation Methods 0.000 description 1
- 101150074488 ddit4 gene Proteins 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002907 exocrine cell Anatomy 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000003052 fractional factorial design Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000056417 human ATXN1 Human genes 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 101150032953 ins1 gene Proteins 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 108091051828 miR-122 stem-loop Proteins 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 239000013648 rAAV12 vector Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 208000030925 respiratory syncytial virus infectious disease Diseases 0.000 description 1
- 230000031070 response to heat Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 102220102504 rs878854150 Human genes 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000011172 small scale experimental method Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 108060007951 sulfatase Proteins 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000005100 tissue tropism Effects 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000010066 viral adhesion Effects 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 108010078375 voltage-dependent calcium channel (P-Q type) Proteins 0.000 description 1
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 description 1
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
本願は配列表を有しており、これはASCIIフォーマットで電子的に提出されており、ここで参照によってその全体が組み込まれる。2022年5月5日に作成された前記ASCIIのコピーは、PC072652APCT_Sequence_Listing_ST25.txtという名称であり、59,346バイトのサイズである。
本開示は、昆虫細胞における組換えアデノ随伴ウイルス(rAAV)ベクターの産生の最適化に関する。特に、本開示は、ウイルスカプシド(cap)タンパク質の完全性が向上し、産生されたrAAVベクターの効力が付随して増大しているrAAVベクターを産生するための、組成物および方法を提供する。
昆虫細胞を、各々が異種配列を含む1つまたは複数の組換えバキュロウイルスと接触させるステップ、ならびに
野生型AAV6のGly115およびArg116に対応するVP1アミノ酸残基の間または別のAAV血清型のVP1タンパク質における対応するアミノ酸の間のクリッピングが15%以下であるrAAVベクターを産生するために十分な時間にわたり、適切な条件下で昆虫細胞を培養するステップ
を含む方法。
昆虫細胞を、各々が異種配列を含む1つまたは複数の組換えバキュロウイルスと接触させるステップ、ならびに
野生型AAV6のGly189およびGlu190に対応するVP1およびVP2アミノ酸残基の間のクリッピングが65%以下であり、かつGly115およびArg116に対応するVP1アミノ酸残基の間のクリッピングが15%以下である、または別のAAV血清型のVP1およびVP2タンパク質における対応するアミノ酸の間のクリッピングが上記指定の割合であるrAAVベクターを産生するために十分な時間にわたり、適切な条件下で昆虫細胞を培養するステップ
を含む方法。
昆虫細胞を、各々が異種配列を含む1つまたは複数の組換えバキュロウイルスと接触させるステップ、ならびに
rAAVベクターのインビトロでの効力が、参照標準と比較して10%~500%の間となり、野生型AAV6のGly115およびArg116に対応するVP1アミノ酸残基の間または別のAAV血清型のVP1タンパク質における対応するアミノ酸の間のクリッピングが15%以下となるように、昆虫細胞を適切な条件下で培養する時間を最適化するステップ
を含む方法。
昆虫細胞を、各々が異種配列を含む1つまたは複数の組換えバキュロウイルスと接触させるステップ、および
AAVベクターのインビトロでの効力が、参照標準と比較して10%~500%の間となり、野生型AAV6のGly189およびGlu190に対応するVP1およびVP2アミノ酸残基の間のクリッピングが65%以下となり、かつGly115およびArg116に対応するVP1アミノ酸残基の間のクリッピングが15%以下となる、または別のAAV血清型のVP1およびVP2タンパク質における対応するアミノ酸の間のクリッピングが上記指定の割合となるように、昆虫細胞を適切な条件下で培養する時間を最適化するステップ
を含む方法。
(i)AAV Repタンパク質および/またはAAV Capタンパク質をコードする異種配列を各々が含む1つまたは2つのヘルパー組換えバキュロウイルス、ならびに
(iii)導入遺伝子をコードする異種配列を2つのAAV逆方向末端反復(ITR)の間に含むベクター組換えバキュロウイルス
と接触させられる、E1からE16のいずれか一項に記載の方法。
(i)昆虫細胞を培養する温度、
(ii)昆虫細胞と接触させるヘルパー組換えバキュロウイルスの量、
(iii)昆虫細胞と接触させるベクター組換えバキュロウイルスベクターの量、および/または
(iv)細胞培養培地中の溶解した酸素の量
を含む、E17に記載の方法。
(i)Sf9細胞を、AAV6のRepタンパク質および/またはAAV6のCapタンパク質をコードする異種配列を各々が含む1つまたは2つのヘルパー組換えバキュロウイルス、ならびに血液凝固因子VIIIをコードする異種配列を2つのAAV2逆方向末端反復(ITR)の間に含むベクター組換えバキュロウイルスと接触させるステップ、ならびに
(ii)Sf9細胞を適切な条件下で108±5時間培養して、野生型AAV6のGly115およびArg116に対応するVP1アミノ酸残基の間のクリッピングが15%以下のrAAV6ベクターを産生するステップ
を含む方法。
(i)Sf9細胞を、AAV6のRepタンパク質および/またはAAV6のCapタンパク質をコードする異種配列を各々が含む1つまたは2つのヘルパー組換えバキュロウイルス、ならびに血液凝固因子VIIIをコードする異種配列を2つのAAV2逆方向末端反復(ITR)の間に含むベクター組換えバキュロウイルスと接触させるステップ、ならびに
(ii)Sf9細胞を適切な条件下で108±5時間培養して、野生型AAV6のGly189およびGlu190に対応するVP1およびVP2アミノ酸残基の間のクリッピングが65%以下であり、かつGly115およびArg116に対応するVP1アミノ酸残基の間のクリッピングが15%以下であるrAAV6ベクターを産生するステップ
を含む方法。
(i)Sf9細胞を、AAV6のRepタンパク質および/またはAAV6のCapタンパク質をコードする異種配列を各々が含む1つまたは2つのヘルパー組換えバキュロウイルス、ならびに血液凝固因子VIIIをコードする異種配列を2つのAAV2逆方向末端反復(ITR)の間に含むベクター組換えバキュロウイルスと接触させるステップ、ならびに
(ii)Sf9細胞を適切な条件下で108±5時間培養して、参照標準と比較して50~150%の間のインビトロでの効力を有し、野生型AAV6のGly115およびArg116に対応するVP1アミノ酸残基の間のクリッピングが15%以下のrAAV6ベクターを産生するステップ
を含む方法。
(i)Sf9細胞を、AAV6のRepタンパク質および/またはAAV6のCapタンパク質をコードする異種配列を各々が含む1つまたは2つのヘルパー組換えバキュロウイルス、ならびに血液凝固因子VIIIをコードする異種配列を2つのAAV2逆方向末端反復(ITR)の間に含むベクター組換えバキュロウイルスと接触させるステップ、ならびに
(ii)Sf9細胞を適切な条件下で108±5時間培養して、参照標準と比較して50~150%の間のインビトロでの効力を有し、野生型AAV6のGly189およびGlu190に対応するVP1およびVP2アミノ酸残基の間のクリッピングが65%以下であり、かつGly115およびArg116に対応するVP1アミノ酸残基の間のクリッピングが15%以下であるrAAV6ベクターを産生するステップ
を含む方法。
別段の定義がない限り、本明細書において使用される全ての技術用語および科学用語は、本発明が属する技術分野の当業者によって一般に理解される意味を有する。本明細書において使用される専門用語は、特定の実施形態のみを記載することを目的としており、本発明を限定することを意図したものではない。本発明の明細書および添付の特許請求の範囲において使用される場合、単数形「a」、「an」、および「the」は、文脈から別段のことが明らかに示されていない限り、複数形も含むことを意図している。
AAV
本開示は、昆虫細胞においてrAAVベクターを産生するための組成物および方法に関する。上記で論じたように、用語「アデノ随伴ウイルス」および/または「AAV」は、直鎖状の一本鎖DNAゲノムおよびそのバリアントを有するパルボウイルスを指す。この用語は、別段のことが必要である場合を除いて、全てのサブタイプ、ならびに天然の形態および組換え形態の両方を網羅する。AAVを含むパルボウイルスは、細胞に侵入し得、核酸(例えば導入遺伝子)を核内に導入し得るため、遺伝子療法ベクターとして有用である。一部の実施形態において、導入された核酸(例えばrAAVベクターゲノム)は、形質導入細胞の核内にエピソームとして存続する環状のコンカテマーを形成する。一部の実施形態において、導入遺伝子は、宿主細胞ゲノム内の特異的部位に、例えばヒト19番染色体上の一部位に挿入される。部位特異的な組み込みは、ランダムな組み込みとは対照的に、予測可能な長期の発現プロファイルをもたらす可能性が高いと考えられている。ヒトゲノム内へのAAVの挿入部位は、AAVS1と呼ばれる。細胞内に導入されると、核酸によってコードされるポリペプチドは細胞によって発現され得る。AAVはヒトにおけるいずれの病原性疾患とも関連していないため、AAVによって送達される核酸は、ヒト対象における疾患、障害、および/または状態の処置のための治療用ポリペプチドを発現させるために使用され得る。
上記で論じたように、「組換えアデノ随伴ウイルス」または「rAAV」は、非ネイティブ配列での内因性ウイルスゲノムの全てまたは一部の置換によって、野生型AAVから区別される。ウイルス内での非ネイティブ配列の組み込みは、ウイルスベクターを「組換え」ベクター、したがって「rAAVベクター」と規定する。rAAVベクターは、所望のタンパク質またはポリペプチド(例えば血液凝固因子)をコードする異種ポリヌクレオチド(すなわち導入遺伝子)を含み得る。組換えベクター配列はAAVカプシドにカプシド形成またはパッケージングされ得、「rAAVベクター」、「rAAVベクター粒子」、「rAAVウイルス粒子」、または単純に「rAAV」と呼ばれる。
本開示は、昆虫細胞内のバキュロウイルス発現ベクター(BEV)系におけるrAAVベクターの産生を増強するための組成物および方法に関する。上記で論じたように、クリッピングされたVP1およびVP2タンパク質のレベルと、相対的なインビトロでの効力との間で逆相関が見られ、この場合、クリッピングされたVP1およびVP2タンパク質のレベルが感染後の時間と共に増大するにつれ、インビトロでの効力は低下した。感染後の時間に伴うクリッピングされたVP1およびVP2タンパク質のこの増大およびインビトロでの効力の付随する低下は、大規模産生(2000L)および小規模産生(2L、10L、または200L)の両方で見られた。
(i)AAV Repタンパク質(例えば、Rep78、Rep68、Rep52、および/またはRep40)をコードする異種配列を含むヘルパー組換えバキュロウイルス、
(ii)AAVカプシド(cap)タンパク質(例えば、AAV VP1、VP2、および/またはVP3タンパク質)をコードする異種配列を含むヘルパー組換えバキュロウイルス、ならびに
(iii)一方は5’末端で、および他方は3’末端で2つのAAV逆方向末端反復(ITR)が隣接する導入遺伝子をコードする異種配列を含むベクター組換えバキュロウイルス
と接触させられる。
(i)AAV Repタンパク質(例えば、Rep78、Rep68、Rep52、および/またはRep40)およびAAVカプシド(cap)タンパク質(例えば、AAV VP1、VP2、および/またはVP3タンパク質)をコードする異種配列を含むヘルパー組換えバキュロウイルス、ならびに
(ii)一方は5’末端で、および他方は3’末端で2つのAAV逆方向末端反復(ITR)が隣接する導入遺伝子をコードする異種配列を含むベクター組換えバキュロウイルス
と接触させられる。
CTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCAAAGCCCGGGCGTCGGGCGACCTTTGGTCGCCCGGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCCT(配列番号10)
である。
AGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGGCTTTGCCCGGGCGGCCTCAGTGAGCGAGCGAGCGCGCAG(配列番号11)
である。
MQIELSTCFFLCLLRFCFSATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYWHVIGMGTTPEVHSIFLEGHTFLVRNHRQASLEISPITFLTAQTLLMDLGQFLLFCHISSHQHDGMEAYVKVDSCPEEPQLRMKNNEEAEDYDDDLTDSEMDVVRFDDDNSPSFIQIRSVAKKHPKTWVHYIAAEEEDWDYAPLVLAPDDRSYKSQYLNNGPQRIGRKYKKVRFMAYTDETFKTREAIQHESGILGPLLYGEVGDTLLIIFKNQASRPYNIYPHGITDVRPLYSRRLPKGVKHLKDFPILPGEIFKYKWTVTVEDGPTKSDPRCLTRYYSSFVNMERDLASGLIGPLLICYKESVDQRGNQIMSDKRNVILFSVFDENRSWYLTENIQRFLPNPAGVQLEDPEFQASNIMHSINGYVFDSLQLSVCLHEVAYWYILSIGAQTDFLSVFFSGYTFKHKMVYEDTLTLFPFSGETVFMSMENPGLWILGCHNSDFRNRGMTALLKVSSCDKNTGDYYEDSYEDISAYLLSKNNAIEPRSFSQNPPVLKRHQREITRTTLQSDQEEIDYDDTISVEMKKEDFDIYDEDENQSPRSFQKKTRHYFIAAVERLWDYGMSSSPHVLRNRAQSGSVPQFKKVVFQEFTDGSFTQPLYRGELNEHLGLLGPYIRAEVEDNIMVTFRNQASRPYSFYSSLISYEEDQRQGAEPRKNFVKPNETKTYFWKVQHHMAPTKDEFDCKAWAYFSDVDLEKDVHSGLIGPLLVCHTNTLNPAHGRQVTVQEFALFFTIFDETKSWYFTENMERNCRAPCNIQMEDPTFKENYRFHAINGYIMDTLPGLVMAQDQRIRWYLLSMGSNENIHSIHFSGHVFTVRKKEEYKMALYNLYPGVFETVEMLPSKAGIWRVECLIGEHLHAGMSTLFLVYSNKCQTPLGMASGHIRDFQITASGQYGQWAPKLARLHYSGSINAWSTKEPFSWIKVDLLAPMIIHGIKTQGARQKFSSLYISQFIIMYSLDGKKWQTYRGNSTGTLMVFFGNVDSSGIKHNIFNPPIIARYIRLHPTHYSIRSTLRMELMGCDLNSCSMPLGMESKAISDAQITASSYFTNMFATWSPSKARLHLQGRSNAWRPQVNNPKEWLQVDFQKTMKVTGVTTQGVKSLLTSMYVKEFLISSSQDGHQWTLFFQNGKVKVFQGNQDSFTPVVNSLDPPLLTRYLRIHPQSWVHQIALRMEVLGCEAQDLY
GGGGGAGGCTGCTGGTGAATATTAACCAAGATCACCCCAGTTACCGGAGGAGCAAACAGGGACTAAGTTCACACGCGTGGTACC(配列番号14)
である。
GTCTGTCTGCACATTTCGTAGAGCGAGTGTTCCGATACTCTAATCTCCCTAGGCAAGGTTCATATTTGTGTAGGTTACTTATTCTCCTTTTGTTGACTAAGTCAATAATCAGAATCAGCAGGTTTGGAGTCAGCTTGGCAGGGATCAGCAGCCTGGGTTGGAAGGAGGGGGTATAAAAGCCCCTTCACCAGGAGAAGCCGTCACACAGATCCACAAGCTCCTG(配列番号15)である。
ATGCAGATCGAGCTCTCCACCTGCTTCTTTCTGTGCCTGTTGAGATTCTGCTTCAGCGCCACCAGGAGATACTACCTGGGGGCTGTGGAGCTGAGCTGGGACTACATGCAGTCTGACCTGGGGGAGCTGCCTGTGGATGCCAGGTTCCCCCCCAGAGTGCCCAAGAGCTTCCCCTTCAACACCTCTGTGGTGTACAAGAAGACCCTGTTTGTGGAGTTCACTGACCACCTGTTCAACATTGCCAAGCCCAGGCCCCCCTGGATGGGCCTGCTGGGCCCCACCATCCAGGCTGAGGTGTATGACACTGTGGTGATCACCCTGAAGAACATGGCCAGCCACCCTGTGAGCCTGCATGCTGTGGGGGTGAGCTACTGGAAGGCCTCTGAGGGGGCTGAGTATGATGACCAGACCAGCCAGAGGGAGAAGGAGGATGACAAGGTGTTCCCTGGGGGCAGCCACACCTATGTGTGGCAGGTGCTGAAGGAGAATGGCCCCATGGCCTCTGACCCCCTGTGCCTGACCTACAGCTACCTGAGCCATGTGGACCTGGTGAAGGACCTGAACTCTGGCCTGATTGGGGCCCTGCTGGTGTGCAGGGAGGGCAGCCTGGCCAAGGAGAAGACCCAGACCCTGCACAAGTTCATCCTGCTGTTTGCTGTGTTTGATGAGGGCAAGAGCTGGCACTCTGAAACCAAGAACAGCCTGATGCAGGACAGGGATGCTGCCTCTGCCAGGGCCTGGCCCAAGATGCACACTGTGAATGGCTATGTGAACAGGAGCCTGCCTGGCCTGATTGGCTGCCACAGGAAGTCTGTGTACTGGCATGTGATTGGCATGGGCACCACCCCTGAGGTGCACAGCATCTTCCTGGAGGGCCACACCTTCCTGGTCAGGAACCACAGGCAGGCCAGCCTGGAGATCAGCCCCATCACCTTCCTGACTGCCCAGACCCTGCTGATGGACCTGGGCCAGTTCCTGCTGTTCTGCCACATCAGCAGCCACCAGCATGATGGCATGGAGGCCTATGTGAAGGTGGACAGCTGCCCTGAGGAGCCCCAGCTGAGGATGAAGAACAATGAGGAGGCTGAGGACTATGATGATGACCTGACTGACTCTGAGATGGATGTGGTGAGGTTTGATGATGACAACAGCCCCAGCTTCATCCAGATCAGGTCTGTGGCCAAGAAGCACCCCAAGACCTGGGTGCACTACATTGCTGCTGAGGAGGAGGACTGGGACTATGCCCCCCTGGTGCTGGCCCCTGATGACAGGAGCTACAAGAGCCAGTACCTGAACAATGGCCCCCAGAGGATTGGCAGGAAGTACAAGAAGGTCAGGTTCATGGCCTACACTGATGAAACCTTCAAGACCAGGGAGGCCATCCAGCATGAGTCTGGCATCCTGGGCCCCCTGCTGTATGGGGAGGTGGGGGACACCCTGCTGATCATCTTCAAGAACCAGGCCAGCAGGCCCTACAACATCTACCCCCATGGCATCACTGATGTGAGGCCCCTGTACAGCAGGAGGCTGCCCAAGGGGGTGAAGCACCTGAAGGACTTCCCCATCCTGCCTGGGGAGATCTTCAAGTACAAGTGGACTGTGACTGTGGAGGATGGCCCCACCAAGTCTGACCCCAGGTGCCTGACCAGATACTACAGCAGCTTTGTGAACATGGAGAGGGACCTGGCCTCTGGCCTGATTGGCCCCCTGCTGATCTGCTACAAGGAGTCTGTGGACCAGAGGGGCAACCAGATCATGTCTGACAAGAGGAATGTGATCCTGTTCTCTGTGTTTGATGAGAACAGGAGCTGGTACCTGACTGAGAACATCCAGAGGTTCCTGCCCAACCCTGCTGGGGTGCAGCTGGAGGACCCTGAGTTCCAGGCCAGCAACATCATGCACAGCATCAATGGCTATGTGTTTGACAGCCTGCAGCTGTCTGTGTGCCTGCATGAGGTGGCCTACTGGTACATCCTGAGCATTGGGGCCCAGACTGACTTCCTGTCTGTGTTCTTCTCTGGCTACACCTTCAAGCACAAGATGGTGTATGAGGACACCCTGACCCTGTTCCCCTTCTCTGGGGAGACTGTGTTCATGAGCATGGAGAACCCTGGCCTGTGGATTCTGGGCTGCCACAACTCTGACTTCAGGAACAGGGGCATGACTGCCCTGCTGAAAGTCTCCAGCTGTGACAAGAACACTGGGGACTACTATGAGGACAGCTATGAGGACATCTCTGCCTACCTGCTGAGCAAGAACAATGCCATTGAGCCCAGGAGCTTCAGCCAGAATCCACCCGTCCTTAAGCGCCATCAGCGCGAGATCACCAGGACCACCCTGCAGTCTGACCAGGAGGAGATTGACTATGATGACACCATCTCTGTGGAGATGAAGAAGGAGGACTTTGACATCTACGACGAGGACGAGAACCAGAGCCCCAGGAGCTTCCAGAAGAAGACCAGGCACTACTTCATTGCTGCTGTGGAGAGGCTGTGGGACTATGGCATGAGCAGCAGCCCCCATGTGCTGAGGAACAGGGCCCAGTCTGGCTCTGTGCCCCAGTTCAAGAAGGTGGTGTTCCAGGAGTTCACTGATGGCAGCTTCACCCAGCCCCTGTACAGAGGGGAGCTGAATGAGCACCTGGGCCTGCTGGGCCCCTACATCAGGGCTGAGGTGGAGGACAACATCATGGTGACCTTCAGGAACCAGGCCAGCAGGCCCTACAGCTTCTACAGCAGCCTGATCAGCTATGAGGAGGACCAGAGGCAGGGGGCTGAGCCCAGGAAGAACTTTGTGAAGCCCAATGAAACCAAGACCTACTTCTGGAAGGTGCAGCACCACATGGCCCCCACCAAGGATGAGTTTGACTGCAAGGCCTGGGCCTACTTCTCTGATGTGGACCTGGAGAAGGATGTGCACTCTGGCCTGATTGGCCCCCTGCTGGTGTGCCACACCAACACCCTGAACCCTGCCCATGGCAGGCAGGTGACTGTGCAGGAGTTTGCCCTGTTCTTCACCATCTTTGATGAAACCAAGAGCTGGTACTTCACTGAGAACATGGAGAGGAACTGCAGGGCCCCCTGCAACATCCAGATGGAGGACCCCACCTTCAAGGAGAACTACAGGTTCCATGCCATCAATGGCTACATCATGGACACCCTGCCTGGCCTGGTGATGGCCCAGGACCAGAGGATCAGGTGGTACCTGCTGAGCATGGGCAGCAATGAGAACATCCACAGCATCCACTTCTCTGGCCATGTGTTCACTGTGAGGAAGAAGGAGGAGTACAAGATGGCCCTGTACAACCTGTACCCTGGGGTGTTTGAGACTGTGGAGATGCTGCCCAGCAAGGCTGGCATCTGGAGGGTGGAGTGCCTGATTGGGGAGCACCTGCATGCTGGCATGAGCACCCTGTTCCTGGTGTACAGCAACAAGTGCCAGACCCCCCTGGGCATGGCCTCTGGCCACATCAGGGACTTCCAGATCACTGCCTCTGGCCAGTATGGCCAGTGGGCCCCCAAGCTGGCCAGGCTGCACTACTCTGGCAGCATCAATGCCTGGAGCACCAAGGAGCCCTTCAGCTGGATCAAGGTGGACCTGCTGGCCCCCATGATCATCCATGGCATCAAGACCCAGGGGGCCAGGCAGAAGTTCAGCAGCCTGTACATCAGCCAGTTCATCATCATGTACAGCCTGGATGGCAAGAAGTGGCAGACCTACAGGGGCAACAGCACTGGCACCCTGATGGTGTTCTTTGGCAATGTGGACAGCTCTGGCATCAAGCACAACATCTTCAACCCCCCCATCATTGCCAGATACATCAGGCTGCACCCCACCCACTACAGCATCAGGAGCACCCTGAGGATGGAGCTGATGGGCTGTGACCTGAACAGCTGCAGCATGCCCCTGGGCATGGAGAGCAAGGCCATCTCTGATGCCCAGATCACTGCCAGCAGCTACTTCACCAACATGTTTGCCACCTGGAGCCCCAGCAAGGCCAGGCTGCATCTGCAGGGCAGGAGCAATGCCTGGAGGCCCCAGGTCAACAACCCCAAGGAGTGGCTGCAGGTGGACTTCCAGAAGACCATGAAGGTGACTGGGGTGACCACCCAGGGGGTGAAGAGCCTGCTGACCAGCATGTATGTGAAGGAGTTCCTGATCAGCAGCAGCCAGGATGGCCACCAGTGGACCCTGTTCTTCCAGAATGGCAAGGTGAAGGTGTTCCAGGGCAACCAGGACAGCTTCACCCCTGTGGTGAACAGCCTGGACCCCCCCCTGCTGACCAGATACCTGAGGATTCACCCCCAGAGCTGGGTGCACCAGATTGCCCTGAGGATGGAGGTGCTGGGCTGTGAGGCCCAGGACCTGTACTGA(配列番号16)である。
GCGGCCTAAGCTTGGAACCATTGCCACCTTCAGGGGGAGGCTGCTGGTGA -50
ATATTAACCAAGATCACCCCAGTTACCGGAGGAGCAAACAGGGACTAAGT-100
TCACACGCGTGGTACCGTCTGTCTGCACATTTCGTAGAGCGAGTGTTCCG-150
ATACTCTAATCTCCCTAGGCAAGGTTCATATTTGTGTAGGTTACTTATTC-200
TCCTTTTGTTGACTAAGTCAATAATCAGAATCAGCAGGTTTGGAGTCAGC-250
TTGGCAGGGATCAGCAGCCTGGGTTGGAAGGAGGGGGTATAAAAGCCCCT-300
TCACCAGGAGAAGCCGTCACACAGATCCACAAGCTCCTGAAGAGGTAAGG-350
GTTTAAGTTATCGTTAGTTCGTGCACCATTAATGTTTAATTACCTGGAGC-400
ACCTGCCTGAAATCATTTTTTTTTCAGGTTGGCTAGTATGCAGATCGAGC-450
TCTCCACCTGCTTCTTTCTGTGCCTGTTGAGATTCTGCTTCAGCGCCACC-500
AGGAGATACTACCTGGGGGCTGTGGAGCTGAGCTGGGACTACATGCAGTC-550
TGACCTGGGGGAGCTGCCTGTGGATGCCAGGTTCCCCCCCAGAGTGCCCA-600
AGAGCTTCCCCTTCAACACCTCTGTGGTGTACAAGAAGACCCTGTTTGTG-650
GAGTTCACTGACCACCTGTTCAACATTGCCAAGCCCAGGCCCCCCTGGAT-700
GGGCCTGCTGGGCCCCACCATCCAGGCTGAGGTGTATGACACTGTGGTGA-750
TCACCCTGAAGAACATGGCCAGCCACCCTGTGAGCCTGCATGCTGTGGGG-800
GTGAGCTACTGGAAGGCCTCTGAGGGGGCTGAGTATGATGACCAGACCAG-850
CCAGAGGGAGAAGGAGGATGACAAGGTGTTCCCTGGGGGCAGCCACACCT-900
ATGTGTGGCAGGTGCTGAAGGAGAATGGCCCCATGGCCTCTGACCCCCTG-950
TGCCTGACCTACAGCTACCTGAGCCATGTGGACCTGGTGAAGGACCTGAA-1000
CTCTGGCCTGATTGGGGCCCTGCTGGTGTGCAGGGAGGGCAGCCTGGCCA-1050
AGGAGAAGACCCAGACCCTGCACAAGTTCATCCTGCTGTTTGCTGTGTTT-1100
GATGAGGGCAAGAGCTGGCACTCTGAAACCAAGAACAGCCTGATGCAGGA-1150
CAGGGATGCTGCCTCTGCCAGGGCCTGGCCCAAGATGCACACTGTGAATG-1200
GCTATGTGAACAGGAGCCTGCCTGGCCTGATTGGCTGCCACAGGAAGTCT-1250
GTGTACTGGCATGTGATTGGCATGGGCACCACCCCTGAGGTGCACAGCAT-1300
CTTCCTGGAGGGCCACACCTTCCTGGTCAGGAACCACAGGCAGGCCAGCC-1350
TGGAGATCAGCCCCATCACCTTCCTGACTGCCCAGACCCTGCTGATGGAC-1400
CTGGGCCAGTTCCTGCTGTTCTGCCACATCAGCAGCCACCAGCATGATGG-1450
CATGGAGGCCTATGTGAAGGTGGACAGCTGCCCTGAGGAGCCCCAGCTGA-1500
GGATGAAGAACAATGAGGAGGCTGAGGACTATGATGATGACCTGACTGAC-1550
TCTGAGATGGATGTGGTGAGGTTTGATGATGACAACAGCCCCAGCTTCAT-1600
CCAGATCAGGTCTGTGGCCAAGAAGCACCCCAAGACCTGGGTGCACTACA-1650
TTGCTGCTGAGGAGGAGGACTGGGACTATGCCCCCCTGGTGCTGGCCCCT-1700
GATGACAGGAGCTACAAGAGCCAGTACCTGAACAATGGCCCCCAGAGGAT-1750
TGGCAGGAAGTACAAGAAGGTCAGGTTCATGGCCTACACTGATGAAACCT-1800
TCAAGACCAGGGAGGCCATCCAGCATGAGTCTGGCATCCTGGGCCCCCTG-1850
CTGTATGGGGAGGTGGGGGACACCCTGCTGATCATCTTCAAGAACCAGGC-1900
CAGCAGGCCCTACAACATCTACCCCCATGGCATCACTGATGTGAGGCCCC-1950
TGTACAGCAGGAGGCTGCCCAAGGGGGTGAAGCACCTGAAGGACTTCCCC-2000
ATCCTGCCTGGGGAGATCTTCAAGTACAAGTGGACTGTGACTGTGGAGGA-2050
TGGCCCCACCAAGTCTGACCCCAGGTGCCTGACCAGATACTACAGCAGCT-2100
TTGTGAACATGGAGAGGGACCTGGCCTCTGGCCTGATTGGCCCCCTGCTG-2150
ATCTGCTACAAGGAGTCTGTGGACCAGAGGGGCAACCAGATCATGTCTGA-2200
CAAGAGGAATGTGATCCTGTTCTCTGTGTTTGATGAGAACAGGAGCTGGT-2250
ACCTGACTGAGAACATCCAGAGGTTCCTGCCCAACCCTGCTGGGGTGCAG-2300
CTGGAGGACCCTGAGTTCCAGGCCAGCAACATCATGCACAGCATCAATGG-2350
CTATGTGTTTGACAGCCTGCAGCTGTCTGTGTGCCTGCATGAGGTGGCCT-2400
ACTGGTACATCCTGAGCATTGGGGCCCAGACTGACTTCCTGTCTGTGTTC-2450
TTCTCTGGCTACACCTTCAAGCACAAGATGGTGTATGAGGACACCCTGAC-2500
CCTGTTCCCCTTCTCTGGGGAGACTGTGTTCATGAGCATGGAGAACCCTG-2550
GCCTGTGGATTCTGGGCTGCCACAACTCTGACTTCAGGAACAGGGGCATG-2600
ACTGCCCTGCTGAAAGTCTCCAGCTGTGACAAGAACACTGGGGACTACTA-2650
TGAGGACAGCTATGAGGACATCTCTGCCTACCTGCTGAGCAAGAACAATG-2700
CCATTGAGCCCAGGAGCTTCAGCCAGAATCCACCCGTCCTTAAGCGCCAT-2750
CAGCGCGAGATCACCAGGACCACCCTGCAGTCTGACCAGGAGGAGATTGA-2800
CTATGATGACACCATCTCTGTGGAGATGAAGAAGGAGGACTTTGACATCT-2850
ACGACGAGGACGAGAACCAGAGCCCCAGGAGCTTCCAGAAGAAGACCAGG-2900
CACTACTTCATTGCTGCTGTGGAGAGGCTGTGGGACTATGGCATGAGCAG-2950
CAGCCCCCATGTGCTGAGGAACAGGGCCCAGTCTGGCTCTGTGCCCCAGT-3000
TCAAGAAGGTGGTGTTCCAGGAGTTCACTGATGGCAGCTTCACCCAGCCC-3050
CTGTACAGAGGGGAGCTGAATGAGCACCTGGGCCTGCTGGGCCCCTACAT-3100
CAGGGCTGAGGTGGAGGACAACATCATGGTGACCTTCAGGAACCAGGCCA-3150
GCAGGCCCTACAGCTTCTACAGCAGCCTGATCAGCTATGAGGAGGACCAG-3200
AGGCAGGGGGCTGAGCCCAGGAAGAACTTTGTGAAGCCCAATGAAACCAA-3250
GACCTACTTCTGGAAGGTGCAGCACCACATGGCCCCCACCAAGGATGAGT-3300
TTGACTGCAAGGCCTGGGCCTACTTCTCTGATGTGGACCTGGAGAAGGAT-3350
GTGCACTCTGGCCTGATTGGCCCCCTGCTGGTGTGCCACACCAACACCCT-3400
GAACCCTGCCCATGGCAGGCAGGTGACTGTGCAGGAGTTTGCCCTGTTCT-3450
TCACCATCTTTGATGAAACCAAGAGCTGGTACTTCACTGAGAACATGGAG-3500
AGGAACTGCAGGGCCCCCTGCAACATCCAGATGGAGGACCCCACCTTCAA-3550
GGAGAACTACAGGTTCCATGCCATCAATGGCTACATCATGGACACCCTGC-3600
CTGGCCTGGTGATGGCCCAGGACCAGAGGATCAGGTGGTACCTGCTGAGC-3650
ATGGGCAGCAATGAGAACATCCACAGCATCCACTTCTCTGGCCATGTGTT-3700
CACTGTGAGGAAGAAGGAGGAGTACAAGATGGCCCTGTACAACCTGTACC-3750
CTGGGGTGTTTGAGACTGTGGAGATGCTGCCCAGCAAGGCTGGCATCTGG-3800
AGGGTGGAGTGCCTGATTGGGGAGCACCTGCATGCTGGCATGAGCACCCT-3850
GTTCCTGGTGTACAGCAACAAGTGCCAGACCCCCCTGGGCATGGCCTCTG-3900
GCCACATCAGGGACTTCCAGATCACTGCCTCTGGCCAGTATGGCCAGTGG-3950
GCCCCCAAGCTGGCCAGGCTGCACTACTCTGGCAGCATCAATGCCTGGAG-4000
CACCAAGGAGCCCTTCAGCTGGATCAAGGTGGACCTGCTGGCCCCCATGA-4050
TCATCCATGGCATCAAGACCCAGGGGGCCAGGCAGAAGTTCAGCAGCCTG-4100
TACATCAGCCAGTTCATCATCATGTACAGCCTGGATGGCAAGAAGTGGCA-4150
GACCTACAGGGGCAACAGCACTGGCACCCTGATGGTGTTCTTTGGCAATG-4200
TGGACAGCTCTGGCATCAAGCACAACATCTTCAACCCCCCCATCATTGCC-4250
AGATACATCAGGCTGCACCCCACCCACTACAGCATCAGGAGCACCCTGAG-4300
GATGGAGCTGATGGGCTGTGACCTGAACAGCTGCAGCATGCCCCTGGGCA-4350
TGGAGAGCAAGGCCATCTCTGATGCCCAGATCACTGCCAGCAGCTACTTC-4400
ACCAACATGTTTGCCACCTGGAGCCCCAGCAAGGCCAGGCTGCATCTGCA-4450
GGGCAGGAGCAATGCCTGGAGGCCCCAGGTCAACAACCCCAAGGAGTGGC-4500
TGCAGGTGGACTTCCAGAAGACCATGAAGGTGACTGGGGTGACCACCCAG-4550
GGGGTGAAGAGCCTGCTGACCAGCATGTATGTGAAGGAGTTCCTGATCAG-4600
CAGCAGCCAGGATGGCCACCAGTGGACCCTGTTCTTCCAGAATGGCAAGG-4650
TGAAGGTGTTCCAGGGCAACCAGGACAGCTTCACCCCTGTGGTGAACAGC-4700
CTGGACCCCCCCCTGCTGACCAGATACCTGAGGATTCACCCCCAGAGCTG-4750
GGTGCACCAGATTGCCCTGAGGATGGAGGTGCTGGGCTGTGAGGCCCAGG-4800
ACCTGTACTGAGGATCCAATAAAATATCTTTATTTTCATTACATCTGTGT-4850
GTTGGTTTTTTGTGTGTTTTCCTGTAACGATCGGGCTCGAGCGC
(配列番号9)である。
前述の明細書は、当業者が本開示を実施することができるようになるために十分であると考えられる。先の記載および実施例は、本開示のある特定の典型的な実施形態を詳述している。しかし、先の記載が文章中ではいかに詳細に記載されているように見えても、本開示は多くの様式で実施され得、本開示は添付の特許請求の範囲およびそのあらゆる均等物に従って解釈されるべきであることが理解されよう。
インビトロでの効力と感染後のバッチ期間との間の関係
PF-07055480と呼ばれるrAAVベクター(本明細書において「SB-525」とも呼ばれる)を、Sf9細胞においてバキュロウイルス発現系を使用して作製した。細胞バンクの細胞を2000Lの産生バイオリアクターへと増殖させ、次いで、逆方向末端反復が隣接する、rep、cap(ヘルパーマスターバキュロウイルスに感染した昆虫細胞またはMBIIC)、および因子VIII遺伝子(ベクターマスターバキュロウイルスに感染した昆虫細胞またはMBIIC)を有する組換えバキュロウイルスに同時感染させた。細胞培養物プロセスを、産生バイオリアクター内で数日間、採取するまで継続し、その後、消化、濾過、および精製を行って、原薬を作製した。
インビトロでの効力の低下の考えられる根本的原因としてのVP1およびVP2のクリッピングの同定
観察されたインビトロでの効力の変動の結果、プロセスおよび分析的観点の両方からインビトロでの効力値の変化の潜在的原動力を理解するために、さらなる研究を行った。質量分析(MS)研究は、インビトロでの効力と相関していると思われる特性を同定した。クリッピングされた形態のVP1/VP2タンパク質という特性を、複数の特性を同時に評価するLC/MS-ペプチドマッピング法(多特性方法またはMAMと呼ばれる)を使用して定量した。このクリッピングされた分子種は、VP1およびVP2タンパク質のアミノ酸残基189Gおよび190Eの間のタンパク質分解性の切断の後に残っているC末端ペプチドとして同定されている。VP1またはVP2のN末端ペプチドは検出不可能であり、製造プロセスの間に明らかになると推定される。図2および表1で示すように、データは、クリッピングされたVP1/VP2タンパク質のレベルと相対的効力との間の逆相関を示している。
インビトロでの効力に対する、細胞培養物の温度、溶解した酸素、組換えバキュロウイルスの量、および感染後のバッチ期間の影響
統計的に計画された実験を構築し、2Lのバイオリアクター内で実行して、rAAVベクターPF-07055480(本明細書において「SB-525」とも呼ばれる)の産生における影響の強いプロセスパラメータを同定した。特に、インビトロでの効力を含むrAAVベクターの特性に対する、産生バイオリアクター内での細胞培養温度、溶解した酸素のレベル、組換えバキュロウイルスの量、および感染後のバッチ期間を含むプロセスパラメータの影響を、この実験において研究した。
中心複合計画は、因子相互作用および二次項の推定を可能にする応答曲面モデリングのための、一般的に使用される計画の1つである。分解能Vを伴う最小一部実施要因計画をこの研究に利用する。いくつかのブロックの間で分けられた全部で60回のランで、6つの因子を研究した。
図6に示すように、バッチ期間に応じて効力が低下するため、研究は、感染後のバッチ期間と効力との間の負の関係を裏付けている。負の関係はまた、培養容積に対するベクターMBIICの添加容積の比率およびインビトロでの効力でも見られる。正の関係は、培養容積に対するヘルパーMBIICの添加容積の比率およびインビトロでの効力で見られる。温度の二次効果が見られるが、効力のための最適な温度は27~28℃の間であり、温度が最適温度から離れると効力は低下する。正の関係は、溶解した酸素およびインビトロでの効力で見られる。
前述の明細書は、当業者が本開示を実施することができるようになるために十分であると考えられる。先の記載および実施例は、本開示のある特定の典型的な実施形態を詳述している。しかし、先の記載が文章中ではいかに詳細に記載されているように見えても、本開示は多くの様式で実施され得、本開示は添付の特許請求の範囲およびそのあらゆる均等物に従って解釈されるべきであることが理解されよう。
Claims (20)
- 組換えアデノ随伴ウイルス(AAV)ベクターのインビトロでの効力を増大させるための方法であって、
昆虫細胞を、各々が異種配列を含む1つまたは複数の組換えバキュロウイルスと接触させるステップ、ならびに、
rAAVベクターのインビトロでの効力が、参照標準と比較して10%~500%の間となり、野生型AAV6のGly189およびGlu190に対応するVP1およびVP2アミノ酸残基の間のクリッピングが65%以下となり、かつGly115およびArg116に対応するVP1アミノ酸残基の間のクリッピングが15%以下となる、または別のAAV血清型のVP1およびVP2タンパク質における対応するアミノ酸の間のクリッピングが上記指定の割合となるように、昆虫細胞を適切な条件下で培養する時間を最適化するステップ
を含む方法。 - rAAVベクターが、約30%~約60%の間の、野生型AAV6のGly189およびGlu190に対応するVP1およびVP2アミノ酸残基の間のクリッピング、ならびに、5%以下の、Gly115およびArg116に対応するVP1アミノ酸残基の間のクリッピング、または上記指定の割合の、別のAAV血清型のVP1およびVP2タンパク質における対応するアミノ酸の間クリッピングを有する、請求項1に記載の方法。
- VP1およびVP2タンパク質でのクリッピングが、キャピラリーゲル電気泳動(CGE)、質量分析(多特性質量分析を含む)、および/またはウェスタンブロットアッセイによって測定される、請求項1から2のいずれか一項に記載の方法。
- rAAVベクターのインビトロでの効力が、参照標準と比較して50%から150%の間である、請求項1から3のいずれか一項に記載の方法。
- インビトロでの効力が、比色アッセイ、発色アッセイ、ELISAベースのアッセイ、定量PCR、および/またはウェスタンブロットを使用して測定される、請求項1から4のいずれか一項に記載の方法。
- 昆虫細胞が、rAAVベクターを昆虫細胞から回収する前に約96時間から約128時間、またはrAAVベクターを昆虫細胞から回収する前に約108±5時間培養される、請求項1から5のいずれか一項に記載の方法。
- 昆虫細胞が、
(i)AAV Repタンパク質および/またはAAV Capタンパク質をコードする異種配列を各々が含む、1つまたは2つのヘルパー組換えバキュロウイルス、ならびに
(ii)導入遺伝子をコードする異種配列を2つのAAV逆方向末端反復(ITR)の間に含む、ベクター組換えバキュロウイルス
と接触させられる、請求項1から6のいずれか一項に記載の方法。 - 野生型AAV6のVP1タンパク質のアミノ酸残基189Gおよび190Eの間のクリッピングが65%以下であり、かつアミノ酸残基115Gおよび116Rの間のクリッピングが15%以下である、または別のAAV血清型のVP1およびVP2タンパク質における対応するアミノ酸の間のクリッピングが上記指定の割合であるrAAVベクターを産生する昆虫細胞を培養するための適切な条件が、
(i)昆虫細胞を培養する温度、
(ii)昆虫細胞と接触させるヘルパー組換えバキュロウイルスの量、
(iii)昆虫細胞と接触させるベクター組換えバキュロウイルスベクターの量、および/または
(iv)細胞培養培地中の溶解した酸素の量
を含む、請求項7に記載の方法。 - 昆虫細胞が、約25℃、約26℃、約27℃、約28℃、約29℃、約30℃、または約31℃の温度で培養される、請求項8に記載の方法。
- 昆虫細胞と接触させるヘルパー組換えバキュロウイルスの量が、全培養容積に対して約0.0022%~約0.0178%の間の容積である、請求項8から9のいずれか一項に記載の方法。
- 昆虫細胞と接触させるベクター組換えバキュロウイルスの量が、全培養容積に対して約0.0022%~約0.0178%の間の容積である、請求項8から10のいずれか一項に記載の方法。
- 培養培地中の溶解した酸素の量が、空気飽和の約20%~約100%である、請求項8から11のいずれか一項に記載の方法。
- 昆虫細胞が、Sf9細胞、Sf21細胞、またはHi5細胞である、請求項1から12のいずれか一項に記載の方法。
- 導入遺伝子が、野生型または機能的バリアントの血液凝固因子、ミニジストロフィン、C1エステラーゼインヒビター、銅輸送P型ATPアーゼ(ATP7B)、銅-亜鉛スーパーオキシドジスムターゼ1(SOD1)、またはミオシン結合タンパク質C3をコードする、請求項7から13のいずれか一項に記載の方法。
- 野生型または機能的バリアント血液凝固因子が、因子VII、因子VIII、または因子IXである、請求項14に記載の方法。
- rAAVが、rAAV1、rAAV3a、rAAV3b、rAAV6、またはrAAV8である、請求項1から15のいずれか一項に記載の方法。
- 血液凝固因子VIIIを含む組換えアデノ随伴ウイルス6(rAAV6)ベクターを産生するための方法であって、
(i)Sf9細胞を、AAV6のRepタンパク質および/またはAAV6のCapタンパク質をコードする異種配列を各々が含む1つまたは2つのヘルパー組換えバキュロウイルス、ならびに血液凝固因子VIIIをコードする異種配列を2つのAAV2逆方向末端反復(ITR)の間に含むベクター組換えバキュロウイルスと接触させるステップ、ならびに
(ii)Sf9細胞を適切な条件下で108±5時間培養して、参照標準と比較して50~150%の間のインビトロでの効力を有し、野生型AAV6のGly189およびGlu190に対応するVP1およびVP2アミノ酸残基の間のクリッピングが65%以下であり、かつGly115およびArg116に対応するVP1アミノ酸残基の間のクリッピングが15%以下であるrAAV6ベクターを産生するステップ
を含む方法。 - (i)昆虫細胞が、約28℃の温度で培養され、
(ii)昆虫細胞と接触させるベクター組換えバキュロウイルスの量が、全培養容積に対して約0.0022%~約0.0178%の間の容積であり、
(iii)昆虫細胞と接触させるヘルパー組換えバキュロウイルスの量が、全培養容積に対して約0.0022%~約0.0178%の間の容積であり、かつ
(iv)培養培地中の溶解した酸素の量が、空気飽和の約20%~約100%である、
請求項17に記載の方法。 - 野生型AAV6のVP1およびVP2タンパク質のアミノ酸残基115Gおよび116Rの間のクリッピングが15%以下であり、かつアミノ酸残基189Gおよび190Eの間のクリッピングが65%以下である、または別のAAV血清型のVP1およびVP2タンパク質における対応するアミノ酸の間のクリッピングが前記指定の割合である、精製された組換えアデノ随伴ウイルス(rAAV)ベクターを含む組成物。
- 参照標準と比較して約50%~150%のインビトロでの効力を有し、VP1およびVP2タンパク質のアミノ酸残基115Gおよび116Rの間のクリッピングが15%以下であり、かつアミノ酸残基189Gおよび190Eの間のクリッピングが65%以下である、野生型または機能的バリアントの血液凝固因子VIIIをコードする導入遺伝子を含む精製された組換えアデノ随伴ウイルス6(rAAV6)ベクターを含む組成物。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163213346P | 2021-06-22 | 2021-06-22 | |
US63/213346 | 2021-06-22 | ||
US202263364296P | 2022-05-06 | 2022-05-06 | |
US63/364296 | 2022-05-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2023002483A true JP2023002483A (ja) | 2023-01-10 |
Family
ID=82595034
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022098808A Pending JP2023002483A (ja) | 2021-06-22 | 2022-06-20 | 昆虫細胞におけるアデノ随伴ウイルスベクターの産生 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4359547A1 (ja) |
JP (1) | JP2023002483A (ja) |
KR (1) | KR20240023638A (ja) |
CA (1) | CA3224755A1 (ja) |
WO (1) | WO2022269466A1 (ja) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009512436A (ja) * | 2005-10-20 | 2009-03-26 | アムステルダム モレキュラー セラピューティクス ビー.ブイ. | 昆虫細胞で産生される改良されたaavベクター |
JP2016534739A (ja) * | 2013-09-12 | 2016-11-10 | バイオマリン ファーマシューティカル インコーポレイテッド | アデノ随伴ウイルス第viii因子ベクター |
JP2017513486A (ja) * | 2014-04-17 | 2017-06-01 | ウニヴェルズィテーツクリニクム ハンブルク−エッペンドルフUniversitaetsklinikum Hamburg−Eppendorf | 脳および脊髄に標的化遺伝子移入するためのウイルスベクター |
US20180163228A1 (en) * | 2016-01-20 | 2018-06-14 | Wuhan Institute Of Physics And Mathematics, Chinese Academy Of Sciences | Method for preparing recombinant adeno-associated virus |
WO2020150556A1 (en) * | 2019-01-18 | 2020-07-23 | Voyager Therapeutics, Inc. | Methods and systems for producing aav particles |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
EP0932694A2 (en) | 1996-09-11 | 1999-08-04 | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Aav4 vector and uses thereof |
US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
ES2313784T3 (es) | 1998-05-28 | 2009-03-01 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Vector aav5 y usos del mismo. |
WO2000028061A2 (en) | 1998-11-05 | 2000-05-18 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same |
US6491907B1 (en) | 1998-11-10 | 2002-12-10 | The University Of North Carolina At Chapel Hill | Recombinant parvovirus vectors and method of making |
AU2001269723B9 (en) | 2000-06-01 | 2006-11-16 | University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
JP3822477B2 (ja) | 2001-09-27 | 2006-09-20 | 住友ゴム工業株式会社 | 空気入りタイヤ及びその製造方法 |
CA2467959C (en) | 2001-11-09 | 2009-03-10 | Robert M. Kotin | Production of adeno-associated virus in insect cells |
US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
DK1649487T3 (da) | 2003-08-01 | 2007-07-02 | Secretary Dept Atomic Energy | Anordning til måling og kvantitativ fastlæggelse af ladede partikelstråler |
AU2004278684B2 (en) | 2003-09-30 | 2011-05-12 | The Trustees Of The University Of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor |
WO2005072364A2 (en) | 2004-01-27 | 2005-08-11 | University Of Florida | A modified baculovirus expression system for production of pseudotyped raav vector |
US7892809B2 (en) | 2004-12-15 | 2011-02-22 | The University Of North Carolina At Chapel Hill | Chimeric vectors |
WO2007120542A2 (en) | 2006-03-30 | 2007-10-25 | The Board Of Trustees Of The Leland Stanford Junior University | Aav capsid library and aav capsid proteins |
US8889641B2 (en) | 2009-02-11 | 2014-11-18 | The University Of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
WO2013063379A1 (en) | 2011-10-28 | 2013-05-02 | University Of North Carolina At Chapel Hill | Cell line for production of adeno-associated virus |
WO2014144229A1 (en) | 2013-03-15 | 2014-09-18 | The University Of North Carolina At Chapel Hill | Methods and compositions for dual glycan binding aav vectors |
JP6600624B2 (ja) | 2013-05-31 | 2019-10-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | アデノ随伴ウイルス変異体及びその使用方法 |
DK3024498T3 (da) | 2013-07-22 | 2020-03-02 | Childrens Hospital Philadelphia | Aav-variant og sammensætninger, fremgangsmåder og anvendelser til genoverførsel til celler, organer og væv |
CN115093464A (zh) | 2013-10-11 | 2022-09-23 | 马萨诸塞眼科耳科诊所 | 预测祖先病毒序列的方法及其用途 |
GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
US10799566B2 (en) | 2015-06-23 | 2020-10-13 | The Children's Hospital Of Philadelphia | Modified factor IX, and compositions, methods and uses for gene transfer to cells, organs, and tissues |
US20190000940A1 (en) | 2015-07-31 | 2019-01-03 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of aadc deficiency |
BR112018008519A2 (pt) | 2015-10-28 | 2018-11-06 | Sangamo Therapeutics Inc | construtos específicos de fígado, cassetes de expressão de fator viii e métodos de uso dos mesmos |
TW202028468A (zh) * | 2018-10-15 | 2020-08-01 | 美商航海家醫療公司 | 用於桿狀病毒/Sf9系統中rAAV之大規模生產的表現載體 |
-
2022
- 2022-06-20 EP EP22743563.3A patent/EP4359547A1/en active Pending
- 2022-06-20 JP JP2022098808A patent/JP2023002483A/ja active Pending
- 2022-06-20 WO PCT/IB2022/055715 patent/WO2022269466A1/en active Application Filing
- 2022-06-20 KR KR1020247002338A patent/KR20240023638A/ko unknown
- 2022-06-20 CA CA3224755A patent/CA3224755A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009512436A (ja) * | 2005-10-20 | 2009-03-26 | アムステルダム モレキュラー セラピューティクス ビー.ブイ. | 昆虫細胞で産生される改良されたaavベクター |
JP2016534739A (ja) * | 2013-09-12 | 2016-11-10 | バイオマリン ファーマシューティカル インコーポレイテッド | アデノ随伴ウイルス第viii因子ベクター |
JP2017513486A (ja) * | 2014-04-17 | 2017-06-01 | ウニヴェルズィテーツクリニクム ハンブルク−エッペンドルフUniversitaetsklinikum Hamburg−Eppendorf | 脳および脊髄に標的化遺伝子移入するためのウイルスベクター |
US20180163228A1 (en) * | 2016-01-20 | 2018-06-14 | Wuhan Institute Of Physics And Mathematics, Chinese Academy Of Sciences | Method for preparing recombinant adeno-associated virus |
WO2020150556A1 (en) * | 2019-01-18 | 2020-07-23 | Voyager Therapeutics, Inc. | Methods and systems for producing aav particles |
Also Published As
Publication number | Publication date |
---|---|
CA3224755A1 (en) | 2022-12-29 |
KR20240023638A (ko) | 2024-02-22 |
WO2022269466A1 (en) | 2022-12-29 |
EP4359547A1 (en) | 2024-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017248840B2 (en) | Methods of enhancing biological potency of baculovirus system-produced recombinant adeno-associated virus | |
JP6619454B2 (ja) | キャプシド | |
JP2019193675A (ja) | アデノ随伴ウイルス第viii因子ベクター | |
AU2016362317A1 (en) | Scalable methods for producing recombinant Adeno-Associated Viral (AAV) vector in serum-free suspension cell culture system suitable for clinical use | |
KR20200033840A (ko) | 개선된 세포 트랜스펙션 및/또는 rAAV 벡터 생산을 위한 증진제 | |
US20170067028A1 (en) | Radiolabeling of adeno associated virus | |
US11702673B2 (en) | Methods of enhancing biological potency of baculovirus system-produced recombinant adeno-associated virus | |
CN110606874A (zh) | 用于基因转移到细胞、器官和组织中的变异aav和组合物、方法及用途 | |
WO2016081927A2 (en) | Genome-modified recombinant adeno-associated virus vectors | |
CA3153133A1 (en) | Adeno-associated virus (aav) systems for treatment of genetic hearing loss | |
US20210147872A1 (en) | Adeno-associated virus (aav) systems for treatment of progranulin associated neurodegenerative diseases or disorders | |
CN114150021B (zh) | 一种包含重叠开放阅读框的基因的表达盒及其在昆虫细胞中的应用 | |
EP3947654A1 (en) | Methods for the manufacture of recombinant viral vectors | |
TW202246516A (zh) | 病毒蛋白之控制表現 | |
TW202045529A (zh) | 用於生產重組aav之組合物及方法 | |
JP2023002483A (ja) | 昆虫細胞におけるアデノ随伴ウイルスベクターの産生 | |
CN117836421A (zh) | 在昆虫细胞中制备腺相关病毒载体 | |
US20220175965A1 (en) | Aav-abcd1 constructs and use for treatment or prevention of adrenoleukodystrophy (ald) and/or adrenomyeloneuropathy (amn) | |
KR20230145357A (ko) | rAAV 및 rBV 생산을 위한 형질전환 시약으로서의 히스티딘이풍부한 펩티드 | |
WO2022271829A1 (en) | Capsid variants and methods of using the same | |
WO2023114816A1 (en) | Recombinant optimized galc constructs and methods for treating galc-associated disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230222 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20230222 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230412 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230705 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230908 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231010 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240219 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20240222 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20240308 |